PEG-MGF

Peptide

Compounding status of PEG-MGF — FDA 503A bulks-list standing, PCAC review history, and state overlays. Each entry links to its source; entries marked reported rest on trade-press coverage until the FDA primary record posts.

Current federal standing

Not compoundable under 503A

PEG-MGF is not on the 503A Bulks List. FDA has scheduled it for the next Pharmacy Compounding Advisory Committee review — by the end of February 2027 (exact date not yet posted). FDA PCAC ↗

We do not sell, source, or supply PEG-MGF. This is a monitoring record from public government sources — not a product, and not advice.

Federal history

No federal status has been published for PEG-MGF yet. We’re monitoring the Federal Register and FDA/PCAC; a standing appears here only with its source document.

State overlays

No state-specific position on PEG-MGF tracked yet. State boards hold independent authority; legislation is monitored via LegiScan and board positions are added as they are verified.

Track PEG-MGF changes

Get the free weekly Brief — FDA and state moves on peptide & GLP-1 compounding, with the source and the date. Members are alerted for their states as soon as a change is published.

Get the free Brief →

← All substances · Informational monitoring from public government sources — not legal or medical advice. No efficacy claims.